Richard B. Vega

Statistics

Publications

Citations

211

H-Index

Active since

2009

Affiliations

Gilead Sciences (United States)(Current)

Novartis (United States)

Novartis (Switzerland)

Novartis Institutes for BioMedical Research

Novartis (China)

Richard B. Vega is an author at Gilead Sciences (United States) specializing in kinase inhibitors, protein kinase inhibitors, and molecular pharmacology.

Publications per year

2009–2011

Publications

A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase

Lauren G. Monovich, Richard B. Vega, Erik L. Meredith et al. · FEBS Letters · 2009 · 58 citations

Life Sciences, Cardiology, Molecular Biology +12

Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors

Erik L. Meredith, Ophelia Ardayfio, Kimberly Beattie et al. · Journal of Medicinal Chemistry · 2010 · 54 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Identification of Potent and Selective Amidobipyridyl Inhibitors of Protein Kinase D

Erik L. Meredith, Kimberly Beattie, Robin Burgis et al. · Journal of Medicinal Chemistry · 2010 · 41 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1

Lauren G. Monovich, Keith A. Koch, Robin Burgis et al. · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · 2009 · 30 citations

Medicine, Cardiology, Molecular Biology +9

3,5-Diarylazoles as novel and selective inhibitors of protein kinase D

Gabriel G. Gamber, Erik L. Meredith, Qingming Zhu et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 28 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

1–5 of 5